Literature DB >> 23653385

An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters.

Kyunghee Yang1, Kathleen Köck, Alexander Sedykh, Alexander Tropsha, Kim L R Brouwer.   

Abstract

Drug-induced cholestasis is an important form of acquired liver disease and is associated with significant morbidity and mortality. Bile acids are key signaling molecules, but they can exert toxic responses when they accumulate in hepatocytes. This review focuses on the physiological mechanisms of drug-induced cholestasis associated with altered bile acid homeostasis due to direct (e.g., bile acid transporter inhibition) or indirect (e.g., activation of nuclear receptors, altered function/expression of bile acid transporters) processes. Mechanistic information about the effects of a drug on bile acid homeostasis is important when evaluating the cholestatic potential of a compound, but experimental data often are not available. The relationship between physicochemical properties, pharmacokinetic parameters, and inhibition of the bile salt export pump among 77 cholestatic drugs with different pathophysiological mechanisms of cholestasis (i.e., impaired formation of bile vs. physical obstruction of bile flow) was investigated. The utility of in silico models to obtain mechanistic information about the impact of compounds on bile acid homeostasis to aid in predicting the cholestatic potential of drugs is highlighted.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  bile acid; drug-induced cholestasis; in silico modeling; pharmacokinetic parameters; physicochemical properties; transporters

Mesh:

Substances:

Year:  2013        PMID: 23653385      PMCID: PMC4369767          DOI: 10.1002/jps.23584

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  153 in total

1.  Structural requirements of the ASBT by 3D-QSAR analysis using aminopyridine conjugates of chenodeoxycholic acid.

Authors:  Xiaowan Zheng; Yongmei Pan; Chayan Acharya; Peter W Swaan; James E Polli
Journal:  Bioconjug Chem       Date:  2010-10-22       Impact factor: 4.774

2.  Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione.

Authors:  Maria Rius; Johanna Hummel-Eisenbeiss; Alan F Hofmann; Dietrich Keppler
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-11-10       Impact factor: 4.052

Review 3.  Nuclear receptors. I. Nuclear receptors and bile acid homeostasis.

Authors:  Bryan Goodwin; Steven A Kliewer
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2002-06       Impact factor: 4.052

4.  Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver.

Authors:  C J Soroka; J M Lee; F Azzaroli; J L Boyer
Journal:  Hepatology       Date:  2001-04       Impact factor: 17.425

5.  Experimental LPS-induced cholestasis alters subcellular distribution and affects colocalization of Mrp2 and Bsep proteins: a quantitative colocalization study.

Authors:  Vadim Zinchuk; Olga Zinchuk; Teruhiko Okada
Journal:  Microsc Res Tech       Date:  2005-06-01       Impact factor: 2.769

Review 6.  Bile duct disorders.

Authors:  André P Geubel; Christine Sempoux; Jacques Rahier
Journal:  Clin Liver Dis       Date:  2003-05       Impact factor: 6.126

Review 7.  Bile acids: regulation of synthesis.

Authors:  John Y L Chiang
Journal:  J Lipid Res       Date:  2009-04-03       Impact factor: 5.922

8.  Computational models for drug inhibition of the human apical sodium-dependent bile acid transporter.

Authors:  Xiaowan Zheng; Sean Ekins; Jean-Pierre Raufman; James E Polli
Journal:  Mol Pharm       Date:  2009 Sep-Oct       Impact factor: 4.939

Review 9.  Enzymes in the conversion of cholesterol into bile acids.

Authors:  Maria Norlin; Kjell Wikvall
Journal:  Curr Mol Med       Date:  2007-03       Impact factor: 2.222

10.  Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.

Authors:  Maria Karlgren; Anna Vildhede; Ulf Norinder; Jacek R Wisniewski; Emi Kimoto; Yurong Lai; Ulf Haglund; Per Artursson
Journal:  J Med Chem       Date:  2012-05-15       Impact factor: 7.446

View more
  27 in total

Review 1.  Cholestatic liver (dys)function during sepsis and other critical illnesses.

Authors:  Marc Jenniskens; Lies Langouche; Yoo-Mee Vanwijngaerden; Dieter Mesotten; Greet Van den Berghe
Journal:  Intensive Care Med       Date:  2015-09-21       Impact factor: 17.440

Review 2.  Sandwich-Cultured Hepatocytes as a Tool to Study Drug Disposition and Drug-Induced Liver Injury.

Authors:  Kyunghee Yang; Cen Guo; Jeffrey L Woodhead; Robert L St Claire; Paul B Watkins; Scott Q Siler; Brett A Howell; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2016-02       Impact factor: 3.534

3.  Evaluation of the Relevance of DILI Predictive Hypotheses in Early Drug Development: Review of In Vitro Methodologies vs BDDCS Classification.

Authors:  Rosa Chan; Leslie Z Benet
Journal:  Toxicol Res (Camb)       Date:  2018-04-18       Impact factor: 3.524

Review 4.  Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction.

Authors:  Antonio Segovia-Zafra; Daniel E Di Zeo-Sánchez; Carlos López-Gómez; Zeus Pérez-Valdés; Eduardo García-Fuentes; Raúl J Andrade; M Isabel Lucena; Marina Villanueva-Paz
Journal:  Acta Pharm Sin B       Date:  2021-11-18       Impact factor: 11.413

5.  Plasma biomarkers of liver injury and inflammation demonstrate a lack of apoptosis during obstructive cholestasis in mice.

Authors:  Benjamin L Woolbright; Daniel J Antoine; Rosalind E Jenkins; Mary Lynn Bajt; B Kevin Park; Hartmut Jaeschke
Journal:  Toxicol Appl Pharmacol       Date:  2013-10-03       Impact factor: 4.219

6.  Bile Acids as Potential Biomarkers to Assess Liver Impairment in Polycystic Kidney Disease.

Authors:  William J Brock; James J Beaudoin; Jason R Slizgi; Mingming Su; Wei Jia; Sharin E Roth; Kim L R Brouwer
Journal:  Int J Toxicol       Date:  2018 Mar/Apr       Impact factor: 2.032

7.  In vitro prediction of drug-induced cholestatic liver injury: a challenge for the toxicologist.

Authors:  Mathieu Vinken
Journal:  Arch Toxicol       Date:  2018-03-24       Impact factor: 5.153

8.  Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity.

Authors:  K Yang; J L Woodhead; P B Watkins; B A Howell; K L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2014-07-28       Impact factor: 6.875

9.  Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability.

Authors:  Delilah F G Hendriks; Lisa Fredriksson Puigvert; Simon Messner; Wolfgang Mortiz; Magnus Ingelman-Sundberg
Journal:  Sci Rep       Date:  2016-10-19       Impact factor: 4.379

10.  Functional human induced hepatocytes (hiHeps) with bile acid synthesis and transport capacities: A novel in vitro cholestatic model.

Authors:  Xuan Ni; Yimeng Gao; Zhitao Wu; Leilei Ma; Chen Chen; Le Wang; Yunfei Lin; Lijian Hui; Guoyu Pan
Journal:  Sci Rep       Date:  2016-12-09       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.